EyePoint pivots resources to DME, Q3 cash rises to $118M
EyePoint announced organizational focus on DURAVYU for Diabetic Macular Edema; phase 3 trials are fully enrolled with top-line data expected in Q4 2027, and the company reported $118 million in cash.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed